ALK - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	APBB1	amyloid beta precursor protein binding family B member 1	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Novel	BIRC6	baculoviral IAP repeat containing 6	ALK mutants bind TKIs Signaling by ALK fusions and activated point mutants
Novel	CLNS1A	chloride nucleotide-sensitive channel 1A	snRNP Assembly
Novel	DLG2	discs large MAGUK scaffold protein 2	Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Neurexins and neuroligins Neurexins and neuroligins Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation
Novel	DNMT3A	DNA methyltransferase 3 alpha	PRC2 methylates histones and DNA RMTs methylate histone arginines SUMOylation of DNA methylation proteins DNA methylation Defective pyroptosis Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	Procaine Decitabine
Novel	DUSP19	dual specificity phosphatase 19
Novel	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Breast cancer Cervical cancer Cholangiocarcinoma Pancreatic cancer Gastric cancer Ovarian cancer Choriocarcinoma Endometrial Cancer Bladder cancer
Novel	HADHB	hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta	Acyl chain remodeling of CL Beta oxidation of myristoyl-CoA to lauroyl-CoA mitochondrial fatty acid beta-oxidation of unsaturated fatty acids Beta oxidation of palmitoyl-CoA to myristoyl-CoA Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA Beta oxidation of octanoyl-CoA to hexanoyl-CoA Beta oxidation of hexanoyl-CoA to butanoyl-CoA
Novel	HES1	hes family bHLH transcription factor 1	Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells NOTCH1 Intracellular Domain Regulates Transcription NOTCH2 intracellular domain regulates transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants RUNX2 regulates osteoblast differentiation RUNX3 regulates NOTCH signaling RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription
Novel	HMGB1	high mobility group box 1	ER-Phagosome pathway Apoptosis induced DNA fragmentation MyD88:MAL(TIRAP) cascade initiated on plasma membrane TAK1-dependent IKK and NF-kappa-B activation MyD88 deficiency (TLR2/4) IRAK4 deficiency (TLR2/4) Pyroptosis Regulation of TLR by endogenous ligand Neutrophil degranulation Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling TRAF6 mediated NF-kB activation	Chloroquine Ethyl pyruvate
Novel	IKBKG	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling FCERI mediated NF-kB activation TAK1-dependent IKK and NF-kappa-B activation activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 SUMOylation of immune response proteins Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 SARS-CoV-2 activates/modulates innate and adaptive immune responses IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation Regulation of NF-kappa B signaling PKR-mediated signaling SLC15A4:TASL-dependent IRF5 activation Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells Modulation of host responses by IFN-stimulated genes	AGRO100 Tarenflurbil	Incontinentia pigmenti Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
Novel	IRS1	insulin receptor substrate 1	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
Novel	JAK3	Janus kinase 3	Interleukin-7 signaling Interleukin-7 signaling Signaling by ALK RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-9 signaling Interleukin-2 signaling Interleukin-21 signaling Interleukin receptor SHC signaling Potential therapeutics for SARS	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one R-348 Ruxolitinib Tofacitinib Baricitinib Fostamatinib Abrocitinib Zanubrutinib	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	MDK	midkine	Signaling by ALK Signaling by ALK NOTCH2 Activation and Transmission of Signal to the Nucleus MDK and PTN in ALK signaling MDK and PTN in ALK signaling
Novel	MSH2	mutS homolog 2	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) Defective Mismatch Repair Associated With MSH3 Defective Mismatch Repair Associated With MSH2 Defective Mismatch Repair Associated With MSH6 TP53 Regulates Transcription of DNA Repair Genes		Ovarian cancer Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome Colorectal cancer
Novel	NLRC4	NLR family CARD domain containing 4	TP53 Regulates Transcription of Caspase Activators and Caspases The IPAF inflammasome The IPAF inflammasome
Novel	NPM1	nucleophosmin 1	Nuclear import of Rev protein Nuclear import of Rev protein SUMOylation of transcription cofactors Deposition of new CENPA-containing nucleosomes at the centromere TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation SARS-CoV-1-host interactions ALK mutants bind TKIs Signaling by ALK fusions and activated point mutants Nuclear events stimulated by ALK signaling in cancer PKR-mediated signaling	Artenimol
Novel	PIK3R1	phosphoinositide-3-kinase regulatory subunit 1	PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Interleukin-7 signaling Interleukin-7 signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events GP1b-IX-V activation signalling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates PI3K/AKT signaling RET signaling RHOA GTPase cycle Extra-nuclear estrogen signaling RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RHOU GTPase cycle RAC3 GTPase cycle RHOV GTPase cycle Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Activated NTRK2 signals through PI3K RHOF GTPase cycle Interleukin receptor SHC signaling Regulation of signaling by CBL Regulation of signaling by CBL Activated NTRK3 signals through PI3K FLT3 Signaling FLT3 Signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by CSF1 (M-CSF) in myeloid cells RND3 GTPase cycle RND2 GTPase cycle RND1 GTPase cycle Signaling by FLT3 fusion proteins Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by FLT3 ITD and TKD mutants Signaling by ALK fusions and activated point mutants Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Signaling by LTK in cancer Signaling by LTK Co-stimulation by ICOS	SF1126 Enzastaurin Wortmannin
Novel	PLCG1	phospholipase C gamma 1	ISG15 antiviral mechanism Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PLCG1 events in ERBB2 signaling DAG and IP3 signaling PLC-gamma1 signalling Synthesis of IP3 and IP4 in the cytosol Downstream signal transduction Signaling by ALK Generation of second messenger molecules Role of phospholipids in phagocytosis Role of phospholipids in phagocytosis PECAM1 interactions EGFR interacts with phospholipase C-gamma DAP12 signaling FCERI mediated MAPK activation FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization Role of second messengers in netrin-1 signaling VEGFR2 mediated cell proliferation VEGFR2 mediated cell proliferation Constitutive Signaling by EGFRvIII Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease RET signaling Activated NTRK2 signals through PLCG1 Activated NTRK2 signals through PLCG1 Erythropoietin activates Phospholipase C gamma (PLCG) Activated NTRK3 signals through PLCG1 Activated NTRK3 signals through PLCG1 FCGR3A-mediated IL10 synthesis Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by ALK fusions and activated point mutants
Novel	PPM1A	protein phosphatase, Mg2+/Mn2+ dependent 1A	Downregulation of SMAD2/3:SMAD4 transcriptional activity Energy dependent regulation of mTOR by LKB1-AMPK

Search Results for: ALK